LIVING DONOR LIVER TRANSPLANTATION FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: SINGLE CENTER EXPERIENCE
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Introduction: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare malignant vascular tumor of the liver. Liver transplantation (LT) is the treatment of choice for patients with advanced-stage HEHE. The aim of this study is to present the results of HEHE patients treated with living donor LT. Material and Method : Between March 2002 and December 2021, 3121 liver transplantations were performed at our institute, 2632 of these were living donor LT. Demographic characteristics, symptoms and clinical findings, laboratory, radiological, and posttransplant histopathological examinations, recurrence rates, disease-free survival, and overall survival rates of the patients were analyzed. Results: The mean age was 41.7 years and %57.6 of the patients were women. Five patients were referred to our institute with signs of chronic liver failure. Four of these patients (57.1%) had Budd-Chiari syndrome. The median follow-up was 35.0 (12.8 - 119.4) months. In all patients, the tumor recurrence rate after transplantation was 71.4%. The overall survival rate for 1 and 5 years was 100 – 57.1% and the disease free survival rate for 1 and 5 years was 71.4 - 38.1%, respectively. Conclusion: Living donor liver transplantation can be considered a viable treatment option for selected HEHE patients. However, multicenter collaborations are crucial to enhance our understanding of this rare malignancy and improve treatment outcomes for these patients.
Açıklama
Anahtar Kelimeler
Kaynak
İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
27
Sayı
4
